Alli Pioneers EU Centralized Process For Nonprescription Switch
This article was originally published in The Tan Sheet
Executive Summary
The European Medicines Agency's clearance of GlaxoSmithKline's weight-loss drug alli for nonprescription status across the European Union marks the first success for a centralized Rx-to-OTC switch process